Johnson & Johnson Vision to Showcase 30 New Sets of Scientific Data on Myopia, Refractive Technologies, IOLs and More at the Association for Research in Vision and Ophthalmology 2023 Meeting
JACKSONVILLE, FL – April 21, 2023 - Johnson & Johnson Vision*, a global leader in eye health and a Johnson & Johnson MedTech Company**, announced that it will present 30 sets of research spanning the spectrum of eye health including myopia, refractive technology, sphere, intraocular lenses, astigmatism, consumer eye health, and vision science at the Association for Research in Vision and Ophthalmology (ARVO) 2023 Live and Virtual Annual Meeting. These posters, papers, and presentations can be accessed through the ARVO 2023 Virtual Meeting Planner.
“Sight is our most precious sense. Yet poor eye health has reached epidemic proportions and access to care remains inequitable and disconnected. Through science and innovation, we are reimagining the scale and impact we can make across a patient’s life to pave the way for a new future of eye health,” said Xiao-Yu Song, Global Head of R&D, Johnson & Johnson Vision.*** “Our R&D team is relentlessly uncovering novel insights across a patient’s eye health journey from addressing global epidemics like myopia in the pediatric eye to addressing refractive error with the ELITA Femtosecond Laser System in the developed eye.”
Myopia Research on Use of Low-Concentration Atropineᵼ and Soft Contact Lenses for Myopia Management:
Myopia is a chronic and progressive disease where the eye grows abnormally long and can lead to significant vision complications later in life.i It poses the biggest eye health threat of the 21st Century,ii with half the world‘s population projected to be myopic by 2050.iii
New data from Johnson & Johnson Vision will present research aiming to better understand myopia management, including use of low-concentration atropineᵼ and soft contact lenses in the pediatric eye.
Efficacy in Myopia Control—Three-year Predictions from the LAMP Study
Bullimore, Mark et al. The purpose of the study is meta-analysis on the three-year Low-Concentration Atropineᵼ for Myopia Progression (LAMP) Study which has greatly enhanced knowledge of the use of low-concentration atropineᵼ for myopia management.
Subjective Vision Differences with Soft Contact Lenses for Myopia Control in Children and Teenagers
Nixon, Alex et al. Soft contact lenses (SCL) for myopia management are often evaluated in younger children (≤12 years), but meaningful myopia progression can occur during the teenage years. The authors found that the subjective visual impact of myopia management SCL may be perceived differently in younger children, with older children more judgmental of their vision experience, at least during the early period of wear. The subjective visual impact by age was design dependent, and a different balance of vision quality and myopia management efficacy may be prudent in older children.
Refractive Research on Flap LASIK Procedures of New Femtosecond Laser:
Johnson & Johnson Vision is presenting data on a new femtosecond laser system which will allow surgeons to perform refractive error correction on patients. The new femtosecond laser system leverages an ultra-precise laser pulse and fast laser delivery.
Flap Cut Pattern Development - Continuous Changes to Success
Gonzalez Calle, Alejandra et al. This study describes the development of a new femtosecond laser and assesses the ease of flap lift compared to iFS Laser, the current commercial flap for LASIK (Laser-Assisted In Situ Keratomileusis). The authors found that laser flap creation patterns and energy levels for the new femtosecond laser were optimized through clinical iterative process, achieving equal or superior ease of flap lift compared to the iFS Laser.
Robust Research from Johnson & Johnson Vision at the ARVO 2023 Meeting includes:
|
TITLE (WITH POSTER / PRESENTATION NUMBER) |
AUTHORS |
PRESENTATION DATE & TIME (CT) |
|
TOPIC: ASTIGMATISM |
|
|
|
Visual Acuity and Refractive Error Quality of Life in Low Astigmats Corrected with Toric Contact Lenses Versus Spectacles (B0343) |
B. Straker et al. |
April 25, |
|
TOPIC: CONSUMER EYE HEALTH |
|
|
|
Blink Triple Care Improves Tear Film Stability in an MGD Rabbit Model (B0365) |
A. Gallois-Bernos et al. |
April 23, |
|
TOPIC: INTRAOCULAR LENS & IMPLANTS |
|
|
|
Assessment of refractive methodologies in patients implanted with extended depth of focus intraocular lenses (EDF IOLs) (C0554) |
E. Li et al. |
April 23, 8:00am – 9:45am |
|
Glare Impact on Mesopic Contrast Sensitivity (B0131) |
E. Papadatou et al. |
April 24, 11:30am – 1:15pm |
|
Chromatic aberration in intraocular lens technologies to extend depth of focus (B0022) |
A. Del Aguila-Carrasco et al. |
April 25, 8:45am – 10:30am |
|
Improvement in Accuracy of Outcomes with Refinement in Refractive Technique for Extended Depth of Focus Intraocular Lenses (IOLs) (B0026) |
S. Vilupuru et al. |
April 25, 8:45m – 10:30am |
|
Through-focus evaluation of IOL-induced visual symptoms in a see-through system (B0024) |
D. Romashchenko et al. |
April 25, 8:45am – 10:30am |
|
Preclinical assessment of through focus dysphotopsia for different IOLs (B0021) |
M. Jenkins et al. |
April 25, 8:45am – 10:30am |
|
Modeling the sensitivity of the accommodative amplitude to the orientation of zonular fibers (C0159) |
L. Feng et al. |
April 27, 8:00am – 9:45am |
|
Preclinical metrics to predict monocular defocus curves from polychromatic optical bench data (C0166) |
A. Heredia et al. |
April 27, 8:00am – 9:45am |
|
Custom-Developed Validated Photographic Method to Evaluate Toric IOL Rotation (C0253) |
R. Vida et al. |
April 27, 8:00am – 9:45am |
|
Verification of the standard model eye versus real corneas (C0165) |
H. Weeber et al. |
April 27, 8:00am – 9:45am |
|
Through-focus visual acuity with intraocular lenses in a compact see-through system compared to clinical data (5420) |
L. Lundström et al. |
April 27, 1:00pm – 1:15pm Location: 255-257 |
|
TOPIC: MYOPIA |
|
|
|
Efficacy in Myopia Control—Three-year Predictions from the LAMP Study (C0499) |
M. Bullimore et al. |
April 23, 12:00pm – 1:45pm |
|
Efficacy in Myopia Control—Odds Versus Absolute Effect (C0506) |
X. Cheng et al. |
April 23, 12:00pm – 1:45pm |
|
Comparison of myopia progression calculators (C0497) |
M. Jong et al. |
April 23, 12:00pm – 1:45pm |
|
Influence of Age and Race on Refractive Error Progression in Myopic Children (C0494) |
C. Smotherman et al. |
April 23, |
|
OCT with integrated video optotype for wide field-of-view choroidal thickness maps in response to defocused stimuli (C0024) |
J. Cathey et al. |
April 26, 10:30am – 12:15pm |
|
Changes in OCT peripapillary retinal nerve fiber layer thickness in myopia children with high cup-disc ratio (C0026) |
C. Audrey et al. |
April 26, 10:30am – 12:15pm |
|
Relationship of macular and choroidal thickness with axial myopia in a Singaporean cohort of myopic children (4370) |
J. Li et al. |
April 26, 3:15pm – 3:30pm |
|
Subjective vision differences with soft contact lenses for myopia control in children and teenagers (C0121) |
A. Nixon et al. |
April 27, 8:00am – 9:45am |
|
TOPIC: REFRACTIVE |
|
|
|
Evaluation of Higher-order Aberrations after Corneal Lenticule Removal with a New Femtosecond Laser System (B0107) |
L. Chen et al. |
April 27, 8:00am – 9:45am |
|
In-vivo Evaluation of a Novel Femtosecond Laser to Create Corneal Lamellar Resections in a Rabbit Model (B0106) |
L. Huang et al. |
April 27, 8:00am – 9:45am |
|
Flap Cut Pattern Development - Continuous Changes to Success (B0108) |
A. Gonzalez-Calle et al. |
April 27, 8:00am – 9:45am |
|
Contrast Sensitivity After A Lenticule Removal Procedure With A New Femtosecond Laser System (B0109) |
M. Laron et al. |
April 27, 8:00am – 9:45am |
|
Preclinical Evaluation of Flap Performance of a New Femtosecond Laser for Corneal Refractive Surgery (B0104) |
A. Umar et al. |
April 27, 8:00am – 9:45am |
|
A New Trajectory Smoothing Algorithm for Radial Lenticule Scanning for ELITA Femtosecond Laser (B0043) |
G. Gao et al. |
April 27, 10:30am – 12:15pm |
|
Programmable Ablation Profile For Improved Lasik Procedure Accuracy (C0182) |
A. Vankov et al. |
April 27, 10:30am – 12:15pm |
|
TOPIC: SPHERE |
|
|
|
Phenotypic distribution of ocular surface cells harvested via impression cytology versus waking eyewash using a novel mass cytometry method (B0385) |
B. Diffey et al. |
April 24, 3:15pm – 5:00pm |
|
TOPIC: VISION SCIENCE |
|
|
|
Modeling the Impact of Pupil Transmission Apodization on Visual Performance under Different Illumination Levels (C0169) |
M. Chen et al. |
April 27, 8:00am – 9:45am |
Media Contact:
Janet Cheng
Johnson & Johnson Vision
Jcheng43@its.jnj.com
###
About Johnson & Johnson Vision At Johnson & Johnson Vision, part of Johnson & Johnson MedTech, we have a bold ambition: to change the trajectory of eye health worldwide. Through our operating companies, we deliver innovation that enables eye care professionals to create better outcomes for patients throughout their lives, with products and technologies that address unmet needs including refractive error, cataracts, and dry eye. In communities with greatest need, we work in collaboration to expand access to quality eye care, and we are committed to helping people see better, connect better, live better. Visit us at jjvision.com, follow @JNJVision on Twitter, Johnson & Johnson Vision on LinkedIn, and @JNJVision on Facebook.
About Johnson & Johnson MedTech
At Johnson & Johnson MedTech, we unleash diverse healthcare expertise, purposeful technology, and a passion for people to transform the future of medical intervention and empower everyone to live their best life possible. For more than a century, we have driven breakthrough scientific innovation to address unmet needs and reimagine health. In surgery, orthopaedics, vision, and interventional solutions, we continue to help save lives and create a future where healthcare solutions are smarter, less invasive, and more personalized.
©Johnson & Johnson Vision Care Inc., 2023. All rights reserved.
*Johnson & Johnson Vision represents the products and services of Johnson & Johnson Surgical Vision, Inc., Johnson & Johnson Vision Care, Inc., and the affiliates of both.
**Johnson & Johnson MedTech comprises the surgery, orthopaedics, vision and interventional solutions businesses within Johnson & Johnson’s MedTech segment.
***Xiao-Yu Song, MD, PhD is an employee of Johnson & Johnson Vision
ᵼ Low dose atropine is currently not approved by any regulatory body for myopia management. It is subject to local regulatory, legal and professional requirements that the eye care professional must understand and comply with to cover all aspects of off-label prescribing in their country.
i Haarman AEG, Enthoven CA, Willem Tideman JL, Tedja MS, Verhoeven VJM, Klaver CCW. The complications of myopia: A review and meta-analysis. Investigative Ophthalmology and Visual Science. 2020;61(4):49-49
ii JJV data on file - Myopia Compendium
iii Holden BA, Fricke TR, Wilson DA, et al. Global Prevalence of Myopia and High Myopia and Temporal Trends from 2000 through 2050. Ophthalmology 2016;123:1036-42
PP2023RF4090
